The minimum duration of sensor data from which glycemic variability can be consistently assessed

Journal of Diabetes Science and Technology

Volumn 8, Issue 2, 2014, Pages 273-276

  Neylon, Orla M ^a   Baghurst, Peter A ^b   Cameron, Fergus J ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

CONGA; Continuous glucose monitoring; Glycemic variation; MAGE; Pediatric; Standard deviation; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADOLESCENT; ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL ARTICLE; CONTINUOUS GLUCOSE MONITORING; CONTINUOUS OVERLAPPING NET GLYCEMIC ACTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC VARIATION; GOLD STANDARD; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAN AMPLITUDE OF GLYCEMIC ACTION; NUTRITIONAL PARAMETERS;

EID: 84900800989     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813519011     Document Type: Article

References (23)

1. Kilpatrick ES, Rigby AS, Atkin SL. For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med. 2010;27(8):868-871.
2. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008;31(suppl 2):S150-S154.
3. Giannini S, Benvenuti S, Luciani P, et al. Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor DHCR24 (Seladin-1). J Endocrinol. 2008;198(3):523-532.
4. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52(11):2795-2804. (Pubitemid 37339710)
5. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288-298.
6. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia. 2001;44(10):1215-1220. (Pubitemid 33010497)
7. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29(7):1486-1490. (Pubitemid 44127568)
8. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 2008;34(6 pt 1):612-616.
9. Cameron FJ, Baghurst PA, Rodbard D. Assessing glycemic variation: why, when and how? Pediatr Endocrinol Rev. 2010;7(suppl 3):432-444.
10. Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther. 2009;11(10):623-633.
11. Baghurst PA, Rodbard D, Cameron FJ. The minimum frequency of glucose measurements from which glycemic variation can be consistently assessed. J Diabetes Sci Technol. 2010;4(6):1382-1385.
12. Keenan DB, Mastrototaro JJ, Zisser H, et al. Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. Diabetes Technol Ther. 2012;14(3):225-231.
13. Abraham EC, Huff TA, Cope ND, Wilson JB Jr, Bransome ED Jr, Huisman TH. Determination of the glycosylated hemoglobins (HB AI) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes. 1978;27(9):931-937. (Pubitemid 9023050)
14. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253-263. (Pubitemid 40586369)
15. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644-655.
16. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009;11(suppl 1):S55-S67.
17. Bugler J. An estimation of the amount of data required to measure glycaemic variability. Adv Technol Treatments Diabetes. 2008:55.
18. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955-962. (Pubitemid 38436607)
19. Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32(11):1947-1953.
20. O'Connell MA, Donath S, O'Neal DN, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009;52(7):1250-1257.
21. Gordin D, Ronnback M, Forsblom C, Makinen V, Saraheimo M, Groop PH. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res Clin Pract. 2008;80(3):e4-e7.
22. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19(10):870-873. (Pubitemid 35177190)
23. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183-190. (Pubitemid 50002199)